Possibilities of noninvasive assessment of the risk of liver fibrosis in patients with type 2 diabetes mellitus
https://doi.org/10.62751/2713-0177-2024-5-3-01
Abstract
The aim. To assess the risk of fibrotic liver changes in patients with type 2 diabetes mellitus and NAFLD using a noninvasive marker, the FIB-4 index.
Material and methods. 161 patients with type 2 diabetes with signs of NAFLD were included. The FIB-4 index was calculated for all patients. A comparative assessment of clinical and laboratory data was carried out in the following groups: group 1 - patients with FIB-4<1.3 – 34.8% (n=56), group 2 – patients with FIB-4>1.3 – 65.2% (n=105). Statistical data processing was carried out using Microsoft Excel 2016 and Jamovi software packages (Version 1.0.1).
Results. Median age of patients in the general group was 59 [49.0; 67.0] years; BMI 31.6 [27.6; 35.7] kg/m2; HbA1c 9.0 [7.70; 10.9] %. The FIB-4 index >1.3 was detected in 65.2% (n=105) of patients; the FIB-4 level ≥2.67 (corresponding to fibrosis) – in 16.8% (n=27). When compared in groups 1 and 2: 51±15.0 years vs. 61 ±10.8 (p<0.001); ALT level – 42.3±28.7 U/L vs. 50.2±64.5 (p<0.001); AST level – 24.1 ±19.4 vs. 42.5±67.3 (p<0.001) U/L. Age ≥60 years increased the probability of a FIB-4 value > 1.3 by 4 times (OR 4,099, 95% CI: 1.9–8.84)), an increase in transaminase levels increased the risk of a FIB-4 value>1.3 by more than 2 times (OR 2.3, 95% CI: 1.02–5.32).
Conclusions. Patients with type 2 diabetes, according to the values of the noninvasive calculation method, have a high risk of developing fibrous changes in the liver, and therefore need more active screening of hepatic dysfunction and timely correction of the main risk factors for its development.
About the Authors
T. Yu. Demidova
Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
Tatiana Yu. Demidova – D. Sci. (Med.), Prof.
Moscow
F. O. Ushanova
Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
Fatima O. Ushanova – C. Sci. (Med.)
Moscow
A. R. Bagilova
Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
Amina R. Bagilova – clinical resident
Moscow
S. V. Panteleeva
Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
Sofia V. Panteleeva – clinical resident
Moscow
References
1. Лазебник Л.Б., Голованова Е.В., Туркина С.В. с соавт. Неалкогольная жировая болезнь печени у взрослых: клиника, диагностика, лечение. рекомендации для терапевтов, третья версия. Экспериментальная и клиническая гастроэнтерология. 2021; (1): 4–52. doi: 10.31146/1682-8658-ecg-185-1-4-52.
2. Younossi ZM, Koenig AB, Abdelatif D et al. Global epidemiology of nonalcoholic fatty liver disease – Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016; 64(1): 73–84. doi: 10.1002/hep.28431.
3. Андреев Д.Н., Маев И.В., Кучерявый Ю. А. Распространенность неалкогольной жировой болезни печени в России: метаанализ. Consilium Medicum. 2023; 25(5): 313–319. doi: 10.26442/20751753.2023.5.202155.
4. Sinha A, Ragan M, Hoerger T et al. Costs and consequence associatiated with newer medications for glycemic control in type 2 diabetes. Diabetes Care. 2010; 33(4): 695–700. doi: 10.2337/dc09-1488.
5. Lazo M., Solga S., Horska A. et al. Effect of a 12-month intensive lifestyle intervention on hepatic steatosis in adults with type 2 diabetes. Diabetes Care, 2010. 33(10): 2156–63. doi: 10.2337/dc10-0856.
6. Петунина Н.А., Тельнова М.Э. Неалкогольная жировая болезнь печени при сахарном диабете 2-го типа. Медицинский совет. 2016; (4): 92–95.
7. Павлов Ч.С. Принципы диагностики и подходы к терапии фиброза и цирроза печени. РМЖ. 2007; (1): 11.
8. Wattacheril JJ, Abdelmalek MF, Lim JK, Sanyal AJ. AGA clinical practice update on the role of noninvasive biomarkers in the evaluation and management of nonalcoholic fatty liver disease: Expert review. Gastroenterology. 2023; 165(4): 1080–88. doi: 10.1053/j.gastro.2023.06.013.
9. Rinella ME, Neuschwander-Tetri BA, Siddiqui MS et al. AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023; 77(5): 1797–835. doi: 10.1097/HEP.0000000000000323.
10. European Association for Study of Liver; Asociacion Latinoamericana para el Estudio del Higado. EASLALEH clinical practice guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol. 2015; 63(1):237–64. doi: 10.1016/j.Jhep.2015.04.006.
11. Xiao G, Zhu S, Xiao X et al. Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: a meta-analysis. Hepatology. 2017; 66(5): 1486–501. doi: 10.1002/hep.29302.
12. Fitzpatrick E., Dhawan A. Noninvasive biomarkers in non-alcoholic fatty liver disease: Current status and a glimpse of the future. World J Gastroenterol. 2014; 20(31):10851–63. doi: 10.3748/wjg.v20.i31.10851.
13. Younossi ZM, Stepanova M, Felix S et al. The combination of the enhanced liver fibrosis and FIB-4 scores to determine significant fibrosis in patients with nonalcoholic fatty liver disease. Aliment Pharmacol Ther. 2023; 57(12): 1417–22. doi: 10.1111/apt.17472.
Review
For citations:
Demidova T.Yu., Ushanova F.O., Bagilova A.R., Panteleeva S.V. Possibilities of noninvasive assessment of the risk of liver fibrosis in patients with type 2 diabetes mellitus. FOCUS. Endocrinology. 2024;5(3):6-11. (In Russ.) https://doi.org/10.62751/2713-0177-2024-5-3-01
Views:
206
Email this article 